Publications

June 2018
23rd Congress of the European Hematology Association (EHA)
Phase 2 Study of X4P-001: A Targeted Oral Therapy for Patients with WHIM Syndrome

2018 American Society of Clinical Oncology (ASCO) Annual Meeting
A Phase 1/2 Study Evaluating the Efficacy and Safety of the Oral CXCR4 Inhibitor X4P-001 in Combination with Axitinib in Patients with Advanced Renal Cell Carcinoma

May 2018
16th Annual Meeting of the Association for Cancer Immunotherapy (CIMT)
The safety, tolerability, and preliminary clinical activity of the CXCR4 inhibitor X4P-001 and nivolumab in renal cell carcinoma patients that are refractory to nivolumab monotherapy

April 2018
2018 American Association for Cancer Research (AACR) Annual Meeting
X4P-001, an Orally Bioavailable CXCR4 Antagonist, Enhances Immune Cell Infiltration and Activation in the Tumor Microenvironment of Melanoma

CXCR4 Inhibition Modulates Tumor Microenvironment and Robustly Inhibits Growth of B16-OVA Melanoma

December 2017
59th Annual Meeting of the American Society for Hematology (ASH)
X4P-001: A Novel Molecularly-Targeted Oral Therapy for WHIM Syndrome

November 2017
Society for Immunotherapy of Cancer (SITC) Annual Meeting
X4P-001, an Orally Bioavailable CXCR4 Antagonist, Increases T Cell Infiltration in Human Metastatic Melanoma

Efficacy and Mechanism of Action of CXCR4 Inhibition in B16 OVA Melanoma Model

October 2017
2017 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
A Phase 1 Dose Finding Study of X4P-001 (An Oral CXCR4 Inhibitor) and Axitinib in Patients with Advanced Renal Cell Carcinoma

September 2017
European Society of Medical Oncology 2017 Congress
A Phase 1 Dose Finding Study of X4P-001 (An Oral CXCR4 Inhibitor) and Axitinib in Patients with Advanced Renal Cell Carcinoma

November 2016
EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium
Anti-tumor activity of X4P-001 in RCC with VEGF inhibitor

April 2016
American Association of Cancer Research (AACR) Annual Meeting 2016
MDSC Trafficking and Function in RCC by CXCR4 in the Presence of a VEGF-R Antagonist is Dependent on HIF-2α Express